Biora Therapeutics, Inc.

Report azionario OTCPK:BIOR.Q

Capitalizzazione di mercato: US$597.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biora Therapeutics Performance degli utili passati

Criteri Il passato verificati 0/6

Biora Therapeutics ha registrato una crescita degli utili a un tasso medio annuo di 21.3%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 36.2%. I ricavi sono stati in diminuzione a un tasso medio annuo di 87.6%.

Informazioni chiave

21.28%

Tasso di crescita degli utili

85.61%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.04%
Tasso di crescita dei ricavi-87.64%
Rendimento del capitale proprion/a
Margine netto-3,988.12%
Ultimo aggiornamento sugli utili30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Seeking Alpha • Sep 13

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics (NASDAQ:BIOR) said on Tuesday the United States Patent and Trademark Office had issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The patent is for methods for using an ingestible device to treat a disease or condition in a patient using jet delivery of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist formulation to the small intestine. GLP-1 receptor agonists are a class of drug approved for type 2 diabetes and weight loss.
Seeking Alpha • Aug 17

Biora Therapeutics: Checking In On The Transformation

Today, we take our first look at the rebranded/refocused Biora Therapeutics in 2022. When we last looked at this company, it was still transitioning from being a genetic testing company to being a developmental drug company. How is the transformation working out to date?  An investment analysis follows in the paragraphs below. Everyone thinks of changing the world, but no one thinks of changing himself." - Leo Tolstoy Today, we put Biora Therapeutics (BIOR) in the spotlight for the first time this year. When we last looked at this entity in the fourth quarter of last year, it was still transitioning from being an entity called Progenity (PROG). The company was in the middle of transforming from its focus as a genetic testing company to being a company focused on developing its drug candidates. Second quarter results just hit the wires this week. Therefore, it seems an opportune time to peak back in on this small cap concern and check in on how its transformation is proceeding. An analysis follows below. Seeking Alpha Company Overview: August Company Presentation The refocused Biora Therapeutics is still based in San Diego. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the GI tract to enhance the treatment of inflammatory bowel diseases. Leadership believe this approach has plenty of potential targets, including holding great promise to more effectively treat Ulcerative Colitis, a large indication. It also is targeting IBD. According to management on its last earnings conference call. Annual global sales for UC drugs are estimated to be approximately $7 billion and the inflammatory bowel disease or IBD space overall is about $19 billion globally. " August Company Presentation August Company Presentation Here is the current development plan for the most advanced candidate in this developmental area, PGN - 600, which is combination of Biora's device and their proprietary formulation of tofacitinib. August Company Presentation The company is also focused on an oral delivery approach via ingestible capsules as an alternative to intramuscular injectable vaccines. This method could eventually see use for proteins as well as monoclonal antibodies. August Company Presentation The replacement of needle injection via an easy to take oral capsule could yield more effective results in a variety of disease areas. The company has a research collaboration with Ionis Pharmaceuticals (IONS) in these initial efforts. Preclinical activities should run into the third quarter of 2023, and are scheduled to start early stage clinical activities by the end of that year. The company estimates the area of the diabetes market it is targeting to be well over $20 billion by 2025. August Company Presentation Management believes the management of diabetes could be vastly improved to name one large target area. August Company Presentation With two core developmental focus areas, the company has numerous candidates in the pipeline. The company's portfolio has numerous patents around the company's intellectual property. That said, its candidates all in the very early stages of the long developmental lifecycle as can be seen above. August Company Presentation
Seeking Alpha • Aug 10

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics (NASDAQ:BIOR), a biotech focused on oral biotherapeutics, surged ~30% on Wednesday to record the highest intraday gain since November after the company announced promising topline data from a study for its targeted therapeutics platform. The recently completed PM-602 was designed to evaluate the Drug Delivery System Capsule (DDS) in patients with ulcerative colitis in a fasted state. According to the data, the device was well tolerated and performed as expected in all UC patients after a single oral ingestion. Accurately identifying the entry into the colon, the device released a saline solution payload that included radioisotopes, leading to distribution across the entire colon in all seven patients. Biora (BIOR) plans to release further information on the study after completing the analysis and intends to submit data for publication. “These human studies are key steps in advancing toward our PGN-600 clinical program, and they also demonstrate the potential of the platform for localized delivery of other drugs,” Chief Executive Adi Mohanty noted. Biora (BIOR) was previously identified as Progenity.

Ripartizione dei ricavi e delle spese

Come Biora Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

OTCPK:BIOR.Q Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
30 Sep 241-363526
30 Jun 241-873731
31 Mar 241-1113830
31 Dec 230-1243730
30 Sep 230-1223829
30 Jun 230-643325
31 Mar 230-523325
31 Dec 220-493824
30 Sep 221-1184227
30 Jun 221-1405233
31 Mar 221-1766741
31 Dec 211-1797346
30 Sep 211-1467649
30 Jun 211-1427549
31 Mar 21-16-1064848
31 Dec 200-1056048
30 Sep 2021-1427551
30 Jun 2039-2078955
31 Mar 20113-21812259
31 Dec 19144-22912063
30 Sep 19120-21111663
31 Dec 18128-12910149

Guadagni di qualità: BIOR.Q al momento non è redditizia.

Margine di profitto in crescita: BIOR.Q al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: BIOR.Q non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 21.3% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di BIOR.Q nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: BIOR.Q non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 54.5% ).

Rendimento del capitale proprio

ROE elevato: Le passività di BIOR.Q superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/05/27 09:30
Prezzo dell'azione a fine giornata2025/05/27 00:00
Utili2024/09/30
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Biora Therapeutics, Inc. è coperta da 5 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Catherine Ramsey SchulteBaird
Steven MahPiper Sandler Companies
Andrew CooperRaymond James & Associates